早期药物发现商ThirtyFiveBio完成过桥轮融资，支持其同类首创GPR35抑制剂计划的持续开发-动脉网

ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures

CISION 等信源发布 2025-04-15 19:00



可切换为仅中文







Capital will Support Continued Development of First-in-Class GPR35 Inhibitor Program for the Treatment of Ulcerative Colitis Utilizing Biomarker-Driven, Precision Medicine Strategy

资本将支持继续开发一流的GPR35抑制剂项目，用于治疗溃疡性结肠炎，采用生物标志物驱动的精准医学策略。

OXFORD, United Kingdom

牛津，英国

，

April 15, 2025

2025年4月15日

/PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced the closing of a bridge round of financing, which included a strategic investment from AbbVie Ventures, along with support from an existing investor Canaan and new investor Mayewell Capital.

/PRNewswire/ -- ThirtyFiveBio Limited是一家开发首创G蛋白偶联受体35（GPR35）小分子抑制剂的生物技术公司，专注于治疗胃肠道（GI）疾病，今天宣布完成了一轮融资，其中包括来自AbbVie Ventures的战略投资，以及现有投资者Canaan和新投资者Mayewell Capital的支持。

The funds will support the continued development of the company's first-in-class GPR35 inhibitor program, which is currently advancing through preclinical development, including investigational new drug (IND)-enabling studies designed to pave the way for initiation of first-in-human clinical trials..

这笔资金将支持公司一流 GPR35 抑制剂项目的持续开发，该项目目前正在临床前开发阶段推进，包括旨在为首次人体临床试验铺平道路的试验性新药 (IND) 相关研究。

'Despite recent advances, patients with Inflammatory Bowel Disease (IBD) are still suffering,' said

“尽管最近有了一些进展，但炎症性肠病（IBD）患者仍然在受苦，”

Timothy Radstake

蒂莫西·拉德斯特克

, M.D., Ph.D., vice president and global head of immunology discovery research, AbbVie. 'Abbvie Ventures invests in opportunities to deliver future pipeline substrates with the potential to break through the therapeutic ceiling in diseases like IBD. We are excited to partner with ThirtyFiveBio to explore the potential therapeutic benefit of targeting GPR35 for the treatment of IBD.'.

医学博士，AbbVie公司副总裁兼全球免疫学发现研究主管。“Abbvie Ventures投资于未来可能突破如IBD等疾病治疗瓶颈的潜在管线产品。我们很高兴与ThirtyFiveBio合作，探索靶向GPR35在IBD治疗中的潜在疗效。”

GPR35 is a genetically validated target in inflammatory bowel disease, including ulcerative colitis. ThirtyFiveBio and its collaborators have shown that gain-of-function variants of GPR35 are associated with disease. Using human biology, patient data, and patient-derived assays, the company is also demonstrating that GPR35 inhibition is a modality with the potential to resolve underlying disease by preventing epithelial cell damage and dysfunction in the gut wall rather than symptomatic inflammation.

GPR35 是炎症性肠病（包括溃疡性结肠炎）中经过基因验证的靶点。ThirtyFiveBio 及其合作者已经证明，GPR35 的功能获得性变异与疾病相关。通过人类生物学、患者数据和患者来源的实验，该公司还表明，抑制 GPR35 是一种可以通过预防肠壁上皮细胞损伤和功能障碍来解决潜在疾病的治疗方式，而不仅仅是缓解症状性炎症。

In this way, GPR35 inhibition can be considered an 'epithelial shield.' As such, GPR35 is a differentiated and orthogonal approach to direct anti-inflammatory modalities with the potential to deliver a novel mechanism of treatment that will improve disease resolution and remission rates..

通过这种方式，GPR35抑制可以被视为一种“上皮屏障”。因此，GPR35是一种与直接抗炎方式有所区别的、独特且独立的途径，有潜力提供一种新的治疗机制，从而提高疾病的缓解率和康复率。

Supported by the company's work with several world-leading academic GPR35 and clinical colitis specialists, ThirtyFiveBio is uniquely pursuing antagonism of GPR35 in patients with ulcerative colitis with first-in-class small molecule inhibitors. The company is leveraging informatic analysis of patient tissue to identify subsets of patients who are enriched for GPR35 inhibitor responsiveness based on their unique genetic signatures and biology. The resulting biomarkers for GPR35 inhibitor responsiveness, once validated, will provide the means for precision patient selection in planned clinical trials..

在公司与几位世界领先的学术GPR35和临床结肠炎专家的合作支持下，ThirtyFiveBio正专注于通过首创的小分子抑制剂拮抗溃疡性结肠炎患者的GPR35。该公司正在利用对患者组织的信息化分析，识别基于其独特基因特征和生物学特性而对GPR35抑制剂响应较高的患者亚群。一旦验证成功，由此产生的GPR35抑制剂响应生物标志物将为计划中的临床试验提供精准患者选择的手段。

'We believe that we occupy a unique and advantageous position within the GPR35-targeted therapeutic space based on our deep understanding of GPR35 biology and how it contributes to GI-related diseases, including colitis and gut cancers. Our discussions with the teams at AbbVie Ventures, as well as Canaan and Mayewell Capital, generated an appreciation for both our competitive differentiation and scientific thought leadership,' said .

“基于我们对GPR35生物学及其在胃肠道相关疾病（包括结肠炎和肠癌）中作用的深刻理解，我们相信自己在针对GPR35的治疗领域占据了独特且有利的位置。我们与AbbVie Ventures、Canaan和Mayewell Capital团队的讨论，使他们对我们既有的竞争优势和科学思想领导力有了充分的认识，”该公司表示。

James Westcott

詹姆斯·韦斯科特

, Ph.D., chief executive officer of ThirtyFiveBio. 'The support from these premier investors offers great validation for the work that our team has already undertaken in this area, as well as the broad therapeutic potential of the platform moving forward. We are eager to continue to advance the program toward the clinic with the goal of establishing proof-of-concept in patients and will be looking for further partners to come on board to support these aims through a syndicated Series A later this year.' .

ThirtyFiveBio首席执行官博士表示：“这些顶级投资者的支持为我们团队在这一领域已经开展的工作提供了极大的认可，同时也验证了该平台未来的广泛治疗潜力。我们渴望继续推动该项目向临床迈进，目标是在患者中建立概念验证，并期待在今年晚些时候通过联合的A轮融资寻找更多合作伙伴来支持这些目标。”

About ThirtyFiveBio

关于ThirtyFiveBio

ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers.

ThirtyFiveBio Limited是一家生物技术公司，正在开发首创的G蛋白偶联受体35（GPR35）小分子抑制剂，用于治疗胃肠道（GI）疾病。该公司在GPR35的生物学及其在胃肠道疾病（包括消化道结肠炎和癌症）中所起的作用方面建立了科学思想领导地位。

ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors with priority molecules in development candidate nomination studies. Created by Molecule to Medicine (MTM), a unique drug discovery and development ecosystem, and Canaan Partners, the company has raised nearly .

ThirtyFiveBio利用其全功能的药物发现平台，鉴定了多个独特类型的首创小分子GPR35抑制剂家族，并优先进行开发候选药物提名研究。该公司由“分子到药物”（Molecule to Medicine，MTM）——一个独特的药物发现与开发生态系统，以及Canaan Partners创建，目前已筹集近。

$25 million

2500万美元

in financing to date. ThirtyFiveBio is headquartered on Milton Park, a key science precinct south of

迄今为止，在融资方面，ThirtyFiveBio 总部位于米尔顿公园，这是位于南部的一个重要科学区。

Oxford, UK

英国牛津

. For more information, please visit:

欲了解更多信息，请访问：

www.thirtyfivebio.com

三十伍生物网站

. To learn more about MTM please visit:

要了解有关 MTM 的更多信息，请访问：